腺苷蛋氨酸联合还原型谷胱甘肽治疗药物性肝损伤患者疗效研究*

doi:10.3969/j.issn.1672-5069.2022.01.017

摘要/Abstract

摘要： 目的探讨应用腺苷蛋氨酸与还原型谷胱甘肽联合治疗药物性肝损伤(DILI)患者的疗效。方法 2017年10月～2020年10月我院收治的90例DILI患者,被随机分为对照组45例和观察组组45例,分别给予还原型谷胱甘肽或还原型谷胱甘肽联合腺苷蛋氨酸治疗。常规检测血清丙二醛(MDA)、超氧化物岐化酶(SOD)和谷胱甘肽过氧化物酶(GSH-Px)。结果本组患者治疗2～6 (3.1±1.4) w,观察组血清ALT、AST和TBIL水平分别为(61.2±8.3)U/L、(54.5±7.4)U/L和(14.4±4.1)μmol/L,显著低于对照组【分别为(86.5±11.5)U/L、(63.1±8.0)U/L和(21.5±5.4)μmol/L,P<0.05】;血清前白蛋白和胆碱酯酶水平分别为(205.5±1.9)mg/L和(5224.1±589.9)u/L,显著高于对照组【分别为(188.5±34.2)mg/L和(4933.9±602.2)u/L,均P<0.05】,而血清总胆汁酸水平为(7.1±1.7)μmol/L,显著低于对照组【(9.5±2.1)μmol/L,P<0.05】;血清丙二醛水平为(4.5±0.7)μmol/L,显著低于对照组【(6.5±0.9)μmol/L,P<0.05】,而血清超氧化物岐化酶和谷胱甘肽过氧化物酶分别为(83.1±7.9)U/L和(125.1±13.7)u/L,显著高于对照组【(75.9±7.2)U/L和(105.5±11.1)u/L,P<0.05】。结论联合应用腺苷蛋氨酸与还原型谷胱甘肽治疗DILI患者近期效果较好,可有效抑制体内炎症反应,改善氧化应激状态和肝功能指标。

关键词: 药物性肝损伤, 腺苷蛋氨酸, 还原型谷胱甘肽, 治疗

Abstract: Objective The aim of this study was to observe the clinical efficacy of adenosylmethionine and reduced glutathione in treating patients with drug-induced liver injury (DILI). Methods 90 patients with DILI were enrolled in our hospital between October 2017 and October 2020, and were randomly divided into control and observation group, with 45 cases in each group. The patients in the control group was treated with reduced glutathione, while those in the observation group was additionally treated with adenosylmethionine at base of reduced glutathione. Serum malondialdehyde (MDA), superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) were routinely detected. Results After two to six (3.1±1.4) week treatment, serum ALT, AST and bilirubin levels in the observation group were (61.2±8.3)U/L, (54.5±7.4)U/L and (14.4±4.1)μmol/L, all significantly lower than [(86.5±11.5)U/L, (63.1±8.0)U/L and (21.5±5.4)μmol/L, respectively, P<0.05] in the control; serum prealbumin and cholinesterase levels were (205.5±1.9)mg/L and (5224.1±589.9)u/L, both significantly higher than [(188.5±34.2)mg/L and (4933.9±602.2)u/L, respectively, P<0.05], while serum total bile acids was (7.1±1.7)μmol/L, significantly lower than [(9.5±2.1)μmol/L, P<0.05] in the control; serum MDA level was (4.5±0.7)μmol/L, significantly lower than [(6.5±0.9)μmol/L, P<0.05], while serum SOD and GSH-Px levels were (83.1±7.9)U/L and (125.1±13.7)u/L, both significantly higher than [(75.9±7.2)U/L and (105.5±11.1) u/L, respectively, P<0.05] in the control group. Conclusion The short-term clinical efficacy of adenosylmethionine and reduced glutathione combination in treatment of patients with DILI is good, which could effectively inhibit inflammatory reactions and oxidative stress, and protect the liver functions.

Key words: Drug-induced liver injury, Adenosylmethionine, Reduced glutathione, Therapy

肖露, 胡弦, 蔡颖珂, 梅凡. 腺苷蛋氨酸联合还原型谷胱甘肽治疗药物性肝损伤患者疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(1): 66-69.

Xiao Lu, Hu Xian, Cai Yingke, et al. Clinical efficacy of adenosylmethionine and reduced glutathione in treating patients with drug-induced liver injury[J]. Journal of Practical Hepatology, 2022, 25(1): 66-69.

参考文献

[1] 刘立伟,赵新颜,贾继东. 2019年欧洲肝脏研究协会临床实践指南:药物性肝损伤的推荐意见. 中华肝脏病杂志,2019,27(6):420-423.
[2] Andrade RJ, Chalasani N, Björnsson ES, et al. Drug-induced liver injury. Nat Rev Dis Primers,2019,5(1):58.
[3] Weaver RJ, Blomme EA, Chadwick AE, et al. Managing the challenge of drug-induced liver injury: a roadmap for the development and deployment of preclinical predictive models. Nat Rev Drug Discov,2020,19(2):131-148.
[4] Devarbhavi H, Raj S. Drug-induced liver injury with skin reactions: drugs and host risk factors, clinical phenotypes and prognosis. Liver Int,2019,39(5):802-811.
[5] 宋芳娇,翟庆慧,贺庆娟, 等.2 820例药物性肝损伤临床分析.中华肝脏病杂志,2020,28(11):954-958.
[6] Palmer M, Regev A, Lindor K, et al. Consensus guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury occurring during clinical trials in adults with chronic cholestatic liver disease. Aliment Pharmacol Ther,2020,51(1):90-109.
[7] Norman BH. Drug induced liver injury (DILI). Mechanisms and medicinal chemistry avoidance/mitigation strategies. J Med Chem,2020,63(20):11397-11419.
[8] 中华医学会肝病学分会药物性肝病学组.药物性肝损伤诊治指南.中华肝脏病杂志,2015,23(11):810-820.
[9] Wang J, Bwayi M, Gee RRF, et al. Pxr-mediated idiosyncratic drug-induced liver injury: mechanistic insights and targeting approaches. Expert Opin Drug Metab Toxicol,2020,16(8):711-722.
[10] 魏明禄,刘建民,陈南清, 等.滋肾益肝方联合多烯磷脂酰胆碱治疗抗结核药物所致急性肝损伤的有效性与安全性研究.中华中医药学刊,2018,36(1):45-48.
[11] Zhou Z, Ye TJ, DeCaro E, et al. Intestinal sirt1 deficiency protects mice from ethanol-induced liver injury by mitigating ferroptosis. Am J Pathol,2020,190(1):82-92.
[12] Andrade RJ, Robles-Díaz M. Diagnostic and prognostic assessment of suspected drug-induced liver injury in clinical practice. Liver Int,2020,40(1):6-17.
[13] 吴杰,谢丽响,修金.多烯磷脂酰胆碱联合双环醇治疗胃癌化疗导致的药物性肝损伤患者疗效及其对血清细胞因子和氧化应激指标水平的影响.实用肝脏病杂志,2020,23(5):666-669.
[14] Sumsion GR, Bradshaw MS 3rd, Beales JT, et al. Diverse approaches to predicting drug-induced liver injury using gene-expression profiles. Biol Direct,2020,15(1):1.
[15] Mullins C, Beaulac K, Sylvia L. Drug-induced liver injury (DILI) with micafungin: the importance of causality assessment. Ann Pharmacother,2020,54(6):526-532.
[16] 王鹤,胡岚,白国强,等.100例新型冠状病毒肺炎重型患者C反应蛋白,血清前白蛋白及胆碱酯酶水平分析及预后.中华内科杂志,2021,60(2):134-138.
[17] Regev A, Palmer M, Avigan MI, et al. Consensus: guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury during clinical trials in patients with nonalcoholic steatohepatitis. Aliment Pharmacol Ther,2019,49(6):702-713.
[18] 李津,易志刚,郭文安,等. 胰升糖素样肽1受体激动剂调节糖尿病合并非酒精性肝病大鼠胰岛素抵抗及肝脏氧化应激损伤的实验研究. 中华内分泌代谢杂志,2017,33(3):228-232.
[19] Hammann F, Schöning V, Drewe J. Prediction of clinically relevant drug-induced liver injury from structure using machine learning. J Appl Toxicol,2019,39(3):412-419.
[20] Ali SE, Waddington JC, Park BK, et al. Definition of the chemical and immunological signals involved in drug-induced liver injury. Chem Res Toxicol, 2020,33(1):61-76.
[21] Leegwater E, Strik A, Wilms EB, et al. Drug-induced liver injury in a patient with coronavirus disease 2019: potential interaction of remdesivir with p-glycoprotein inhibitors. Clin Infect Dis, 2021,72(7):1256-1258.

腺苷蛋氨酸联合还原型谷胱甘肽治疗药物性肝损伤患者疗效研究^*

Clinical efficacy of adenosylmethionine and reduced glutathione in treating patients with drug-induced liver injury

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	孙皆齐, 姜绍文, 汪铮. 应用艾尔巴韦/格拉瑞韦治疗基因1b型慢性丙型肝炎初治和经治患者效果对比研究^*[J]. 实用肝脏病杂志, 2022, 25(2): 195-198.
[2]	马国斌, 赵晓宏, 赵鹏, 杨冰. 自身免疫性肝炎患者肝组织IL-35表达和外周血髓样抑制细胞百分比变化临床意义探讨^*[J]. 实用肝脏病杂志, 2022, 25(2): 199-202.
[3]	曾议, 李国, 李红翠, 彭雅松, 田峰, 王小军. 熊去氧胆酸治疗原发性胆汁性胆管炎患者疗效及对血清Nrf2和HO-1水平的影响[J]. 实用肝脏病杂志, 2022, 25(2): 211-214.
[4]	陈凯, 居峰. 多烯磷脂酰胆碱联合扶正化瘀片治疗非酒精性脂肪性肝病患者肝脏超声脂肪变性评分变化^*[J]. 实用肝脏病杂志, 2022, 25(2): 219-222.
[5]	王本贤, 李伟, 李东生, 李华. 腹水浓缩回输联合抗感染治疗失代偿期乙型肝炎肝硬化患者疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(2): 247-250.
[6]	刘松涛, 刘梅, 渠亚超, 李瑞利, 邵晨, 闾军. 4例原发性肝脏神经内分泌肿瘤临床分析及文献复习[J]. 实用肝脏病杂志, 2022, 25(2): 251-254.
[7]	王婵, 沈长清, 吴晓琼, 邓程伟, 谢文蕊. 表柔比星药物洗脱微球肝动脉化疗栓塞术治疗不可手术切除的原发性肝癌患者临床疗效和安全性分析[J]. 实用肝脏病杂志, 2022, 25(2): 259-262.
[8]	周建, 陆旭, 朱岩举, 王庆元, 冯明明, 郭胜利. 腹腔镜与开腹肝切除术治疗肝内胆管细胞癌患者疗效与安全性研究[J]. 实用肝脏病杂志, 2022, 25(2): 275-278.
[9]	刘海生, 宁纯民, 孙文兵. 血管瘤剥脱术和肝切除术治疗肝血管瘤患者疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(2): 279-282.
[10]	王思琪, 申远, 崔振兴, 李岩. 腹腔镜穿刺置管引流术与腹腔镜切开置管引流术治疗肝脓肿患者疗效观察[J]. 实用肝脏病杂志, 2022, 25(2): 283-286.
[11]	何翼彪, 王智鹏, 白磊. 三维可视化系统联合纤维胆道镜治疗肝胆管结石患者近期疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(2): 287-290.
[12]	田婉婷, 陈保银, 马竹芳, 徐菁, 马臻奇. 改良鼻胆管与普通鼻胆管引流在经胆囊入路治疗细径胆总管结石患者疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(2): 291-294.
[13]	尹天泉, 赵程, 刘岩. 参附注射液治疗脓毒症并发急性肝损伤患者疗效研究[J]. 实用肝脏病杂志, 2022, 25(2): 295-296.
[14]	郑淑颖, 郭欢欢, 程长浩, 冯珍珍. 索非布韦联合雷迪帕韦治疗慢性丙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(1): 26-29.
[15]	吕春卉, 李大炜, 王小洁, 康晓平, 韩宗晟, 朱允. 二甲双胍联合辛伐他汀治疗非酒精性脂肪性肝病合并2型糖尿病患者疗效研究[J]. 实用肝脏病杂志, 2022, 25(1): 50-53.